- Home
- MMI vs ELVN Comparison
MMI vs ELVN Comparison
Compare MMI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMI
- ELVN
- Stock Information
- Founded
- MMI 1971
- ELVN 2016
- Country
- MMI United States
- ELVN United States
- Employees
- MMI N/A
- ELVN N/A
- Industry
- MMI Real Estate
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- MMI Finance
- ELVN Health Care
- Exchange
- MMI Nasdaq
- ELVN Nasdaq
- Market Cap
- MMI 1.2B
- ELVN 1.2B
- IPO Year
- MMI 2013
- ELVN 2020
- Fundamental
- Price
- MMI $27.95
- ELVN $20.19
- Analyst Decision
- MMI Hold
- ELVN Strong Buy
- Analyst Count
- MMI 1
- ELVN 5
- Target Price
- MMI N/A
- ELVN $41.20
- AVG Volume (30 Days)
- MMI 123.3K
- ELVN 563.5K
- Earning Date
- MMI 11-07-2025
- ELVN 11-12-2025
- Dividend Yield
- MMI 1.77%
- ELVN N/A
- EPS Growth
- MMI N/A
- ELVN N/A
- EPS
- MMI N/A
- ELVN N/A
- Revenue
- MMI $725,903,000.00
- ELVN N/A
- Revenue This Year
- MMI $9.50
- ELVN N/A
- Revenue Next Year
- MMI $17.73
- ELVN $20.05
- P/E Ratio
- MMI N/A
- ELVN N/A
- Revenue Growth
- MMI 17.89
- ELVN N/A
- 52 Week Low
- MMI $27.61
- ELVN $13.30
- 52 Week High
- MMI $42.80
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- MMI 26.76
- ELVN 52.19
- Support Level
- MMI $28.25
- ELVN $19.02
- Resistance Level
- MMI $29.38
- ELVN $20.66
- Average True Range (ATR)
- MMI 0.70
- ELVN 1.04
- MACD
- MMI -0.29
- ELVN 0.10
- Stochastic Oscillator
- MMI 6.22
- ELVN 71.76
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.